Vernalis PLC 's management hasn't had much time to rest this summer. In June, it signed a deal with Biogen Idec Inc. for the UK firm's Phase I Parkinson's disease treatment V2006 and in mid-August the company announced that Novartis AG 's Novartis Institutes for Biomedical Research would exercise its option on Vernalis' preclinical cancer program targeting Hsp90. [See Deal][See Deal] But the summer's most prominent objective for the Vernalis team was re-licensing its marketed frovatriptan (Frova) migraine product.
When Vernalis reacquired North American rights to Frova in March 2004 from Elan Corp. PLC , Vernalis CEO Simon...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?